Keyur Parikh, MD
Gastroenterology · Mentor, OHNPI 1700157450
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,313 of the $89,199 with a category attached, or 82.2%. AbbVie accounts for 96.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $47,287, more than ten times the $514 reported in 2019. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $285.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$86K
- Pfizer$450
- Apollo Endosurgery US Inc$295
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$273
- Takeda Pharmaceuticals U.S.A., Inc.$233
- Johnson & Johnson$195
- plus $2K from 29 others
Across 19 payments — averaging $16,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$171K
- Bausch Health US, LLC$113K
- Regeneron$26K
What the payments were for
- Speaking & faculty fees$73,31382%
- Travel & lodging$9,06610%
- Food & beverage$6,7418%
- Education$80%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 152 | $86,114 |
| Pfizer | 25 | $450 |
| Apollo Endosurgery US Inc | 3 | $295 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $233 |
| Johnson & Johnson | 12 | $195 |
| Phathom Pharmaceuticals, Inc. | 12 | $182 |
| Vivus LLC | 11 | $159 |
| Gilead | 9 | $150 |
| Merck | 8 | $140 |
| QOL Medical, LLC | 6 | $119 |
| Braintree Laboratories, Inc. | 3 | $100 |
| Lilly USA, LLC | 3 | $77 |
| Celltrion USA Inc. | 3 | $65 |
| Ipsen Biopharmaceuticals, Inc | 3 | $59 |
| Novo Nordisk | 3 | $53 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| Sanofi | 2 | $47 |
| Intercept Pharmaceuticals, Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Ardelyx, Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Evoke Pharma, Inc. | 2 | $30 |
| Shionogi Inc | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Bristol Myers Squibb | 2 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Romark Laboratories, LC | 1 | $19 |
| Organon | 1 | $18 |
| Stryker | 1 | $18 |
| Medtronic | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,199 in reported general payments places this provider in the 90th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 12 | $100,384 |
| CreonLipase/Protease/Amylase | 29 | $70,922 |
| LinzessLinaclotide | 17 | $13,349 |
| Mesalamine | 17 | $10,022 |
| Colesevelam Hcl | 41 | $7,116 |
| Pantoprazole Sodium | 363 | $3,999 |
| Budesonide EcBudesonide | 11 | $3,112 |
| Omeprazole | 154 | $1,879 |
| Dicyclomine Hcl | 74 | $1,451 |
| Famotidine | 78 | $1,112 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 59 | $713 |
| Ondansetron Hcl | 12 | $318 |
| Amitriptyline Hcl | 12 | $203 |
| Metronidazole | 12 | $152 |
| Nystatin | 13 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $86,114 | $84,27046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Mentor
- Keith FriedenbergMentor$124K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.